Rapid Line (RPDL) Launches BCI-Powered KIDWIN 3.0: Next-Gen Cognitive Learning Platform
Solving Education's Biggest Challenges: Why Brains Need 'Smart Learning'
Traditional education often struggles with three critical gaps:
Rapid Line's BCI technology addresses these issues head-on. Through a child-friendly, non-invasive wearable device (in development), it captures real-time electroencephalogram (EEG) signals to monitor a child's focus levels, memory states, and cognitive load - providing scientific insights to optimize learning paths.
KIDWIN 3.0: The 'Brain-Driven' Learning Revolution
The upgraded KIDWIN platform introduces three revolutionary features designed to work in harmony with how the brain learns best:
Why Rapid Line Leads the BCI Education Era
Visionary Leadership: 'Unlocking Every Brain's Potential'
Jiang Jian, CEO of Rapid Line Inc., stated: 'Education should not be a one-way infusion, but a natural release of the brain's potential. With BCI, we're moving beyond 'teaching to the test'-our goal is to empower every child to grow in the way that best suits their unique mind.'
About Rapid Line Inc.
Rapid Line Inc. is a development-stage company operating in the online education market segment. The company provides useful and effective type of online learning services, additional play-based studying in a form of quiz tool according to a school program available from anywhere using the phone and internet connection. Its online service provides a high quality, fundamental, comprehensive additional education through its mobile application 'KIDWIN' for Android and iOS mobile OS.
Media Contact
Email: [email protected]
Phone: +86-15274931919
SOURCE: Rapid Line Inc
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V
SINGAPORE, July 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, announced today that the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for SCG101V, marking the first-ever investigational cell therapy to enter regulatory approved Phase 1/2 clinical trial for chronic hepatitis B virus (HBV) infection. SCG101 is designed to cure chronic hepatitis B by eliminating HBV cccDNA and HBV-DNA integration within HBV-infected hepatocytes, which are the fundamental source of persistent infection and antigen production. These infected hepatocytes serve as the long-term viral reservoir that current antiviral therapies fail to eradicate. "SCG101 is designed to mimic the natural immune response observed in individuals who are able to clear HBV infection spontaneously. HBV-specific T cells play a central role in this process and, remarkably, through genetic engineering of T cells, we were able to replicate this natural process as demonstrated in our preclinical models and clinical data in hepatocellular carcinoma, providing strong evidence that this promise holds true in hepatitis B patients", said Professor Ulrike Protzer, Scientific Founder of SCG Cell Therapy and Director of Institute of Virology Technical University of Munich / Helmholtz Munich. In Phase 1 clinical trial of SCG101 in patients with HBV-related hepatocellular carcinoma (HCC), SCG101 demonstrated a good safety profile and sustained clearance of serum hepatitis B surface antigen (HBsAg), even in heavily pre-treated patients. Among the treated patients, 94% of patients had previously received nucleoside analogue (NA) antiviral therapy, and 72% presented with baseline liver cirrhosis. Following a single infusion of SCG101, all patients experienced a rapid decline in HBsAg level. Notably, 94% achieved a 1.0–4.6 log₁₀ reduction in HBsAg within 28 days, with HBsAg levels remained <100 IU/mL for up to one year without rebound. Furthermore, 23% of patients achieved complete HBsAg loss, a critical benchmark for a cure. Professor Niu Jinqi, Vice President and Chief Physician of The First Hospital of Jilin University, commented: "SCG101 has demonstrated significant breakthrough potential in HBV-related liver cancer, remarkably, achieving HBsAg loss following a single dose. This IND approval by the NMPA marks a pioneering step toward a functional cure for chronic hepatitis B. We are excited about the prospects of this therapy and the benefit it could bring to millions of patients, helping to reduce the burden of liver disease in China and globally". Chronic HBV infection affects an estimated 300 million people globally and is a leading cause of liver cirrhosis and hepatocellular carcinoma, contributing to more than 820,000 deaths each year. While current standard-of-care therapies can suppress viral replication, they rarely achieve a functional cure and therefore cannot fundamentally halt disease progression. "This IND clearance represents a historic milestone—not only for SCG but for the broader field of hepatitis B treatment. With indications across HBV-related hepatocellular carcinoma, HBV-related cholangiocarcinoma, and chronic hepatitis B, this IND clearance further validates our development strategy—expanding from virus-induced cancers to chronic infectious diseases", said Christy Ma, Chief Executive Officer of SCG Cell Therapy. "SCG101 is the first cell therapy product to receive regulatory approval to enter a Phase 1/2 clinical trial specifically for HBV and HBV-induced cancer, and we are proud to lead the way in advancing toward a long-term functional cure. We remain on track for initiation of a pivotal study, following the recent completion of our Phase 1 study in patients with HBV-HCC. We look forward to sharing additional clinical data as we continue to push the boundaries of what's possible in cell therapy." – END – About SCG101 SCG101 is an investigational autologous T cell receptor (TCR) T cell therapy designed to selectively target specific epitope of the hepatitis B surface antigen (HBsAg). Powered by SCG's proprietary GianTCR™ screening platform, which enables the discovery of natural, high-affinity, high-avidity TCRs against intracellular antigens presented via the major histocompatibility complex (MHC). SCG101 delivers precise immune-mediated clearance of infected and malignant cells demonstrating significant tumour inhibition and the eradication of HBV covalently closed circular DNA (cccDNA) in preclinical and clinical studies. About HBV Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection is a major global health issue, affecting nearly 300 million people across the world. Approximately 1.1 million people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options. About SCG Cell Therapy SCG Cell Therapy is a leading biotechnology company dedicated to developing novel immunotherapies for infectious diseases and associated cancers. The company focuses on targeting some of the most common cancer-causing infections, including Helicobacter pylori, HPV, HBV, and EBV. SCG is advancing a broad pipeline of TCR-based therapeutics aimed at preventing and curing infection-related cancers. Headquartered in Singapore, SCG operates across Singapore, China, and Germany, leveraging regional strengths to cover the entire value chain, from innovative drug research and discovery to manufacturing, clinical development, and commercialization. For more information, please visit View original content: SOURCE SCG Cell Therapy Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
41 minutes ago
- Bloomberg
Trump's August Tariff Deadline ‘Not 100% Firm,' Talks Possible
My colleague Katia makes a good point about how China factors into all of this. As we've reported the world's second-largest economy is on watch for how Trump has attempted to shut trade loopholes that impact China. The Chinese stock market opened slightly higher today, following some of its Asian peers. A key gauge of Chinese stocks traded in Hong Kong rose as much as 0.6% before trimming some gains. The onshore CSI 300 benchmark is also up 0.2% as of 9:53 a.m. Hong Kong time. The MSCI Asia Pacific index swings between gains and losses.
Bloomberg
44 minutes ago
- Bloomberg
China Shuns Costly LNG Imports Even as Summer Power Demand Rises
Sweltering temperatures are pushing up appetite for electricity in China — just not yet enough to revive the country's spot purchases of costly liquefied natural gas. Traders hoping for a recovery in spot LNG deals had been watching for a surge in summer demand along China's eastern seaboard. Scorching heat has indeed created those spikes, except that cheap coal, higher-than-usual inventories of power-station fuels and a continued increase in renewable capacity have filled the gap and limited the risk of seasonal blackouts.
